PharmaEssentia Corp (藥華醫藥) yesterday said it had gained approval from the Food and Drug Administration to proceed with a phase III global clinical trial to add hepatitis B as an indication for ropeginterferon alfa-2b, its newly approved polycythemia vera (PV) drug.
The company is planning to enroll 212 e-antigen positive hepatitis B patients worldwide and complete the phase III trial over the next two to three years, it said.
The announcement came after the European Medicines Agency earlier this week gave marketing authorization for the PV drug in the eurozone.
The parameters of the clinical trial leverages biomarkers to identify patients who are more likely to respond to the company’s interferon drug, PharmaEssentia chief executive Lin Ko-chung (林國鐘) said.
Hepatitis B is a highly contagious disease with more than 400 million chronic carriers worldwide and it leads to 1 million deaths a year, the company said.
There are between 10 million and 30 million new cases each year, and between 5 and 10 percent are likely to be hereditary carriers that do not show symptoms of the disease due to their genetic traits.
Studies show that 30 percent of the hereditary carriers with high concentrations of hepatitis B core antigen are likely to respond well to interferon treatments, the company said, noting that its phase III trial is targeting those patients.
Chronic infections such as hepatitis B are currently treated with nucleoside analogs or long-acting interferons such as Roche Holding AG’s Pegasys, but each has its shortcomings.
Nucleoside analogs have high toxicity profiles and only suppress the disease, while Pegasys has limited effectiveness and requires frequent injections.
Phase I and II trials showed that compared with Pegasys, PharmaEssentia’s interferon produced shorter seroconversion periods — the time it takes for patients to develop antibodies against e-antigen that can be detected in blood tests — among select patients, it said.
The interferon requires only biweekly injections and has milder side effects, and could be an option to meet currently unmet medical needs, the company said.
The company said it is working on the phase III trial with Linkou Chang Gung Memorial Hospital and Keelung Chang Gung Memorial Hospital.
Among the rows of vibrators, rubber torsos and leather harnesses at a Chinese sex toys exhibition in Shanghai this weekend, the beginnings of an artificial intelligence (AI)-driven shift in the industry quietly pulsed. China manufactures about 70 percent of the world’s sex toys, most of it the “hardware” on display at the fair — whether that be technicolor tentacled dildos or hyper-realistic personalized silicone dolls. Yet smart toys have been rising in popularity for some time. Many major European and US brands already offer tech-enhanced products that can enable long-distance love, monitor well-being and even bring people one step closer to
TRANSFORMATION: Taiwan is now home to the largest Google hardware research and development center outside of the US, thanks to the nation’s economic policies President Tsai Ing-wen (蔡英文) yesterday attended an event marking the opening of Google’s second hardware research and development (R&D) office in Taiwan, which was held at New Taipei City’s Banciao District (板橋). This signals Taiwan’s transformation into the world’s largest Google hardware research and development center outside of the US, validating the nation’s economic policy in the past eight years, she said. The “five plus two” innovative industries policy, “six core strategic industries” initiative and infrastructure projects have grown the national industry and established resilient supply chains that withstood the COVID-19 pandemic, Tsai said. Taiwan has improved investment conditions of the domestic economy
Malaysia’s leader yesterday announced plans to build a massive semiconductor design park, aiming to boost the Southeast Asian nation’s role in the global chip industry. A prominent player in the semiconductor industry for decades, Malaysia accounts for an estimated 13 percent of global back-end manufacturing, according to German tech giant Bosch. Now it wants to go beyond production and emerge as a chip design powerhouse too, Malaysian Prime Minister Anwar Ibrahim said. “I am pleased to announce the largest IC (integrated circuit) Design Park in Southeast Asia, that will house world-class anchor tenants and collaborate with global companies such as Arm [Holdings PLC],”
MAJOR BENEFICIARY: The company benefits from TSMC’s advanced packaging scarcity, given robust demand for Nvidia AI chips, analysts said ASE Technology Holding Co (ASE, 日月光投控), the world’s biggest chip packaging and testing service provider, yesterday said it is raising its equipment capital expenditure budget by 10 percent this year to expand leading-edge and advanced packing and testing capacity amid strong artificial intelligence (AI) and high-performance computing chip demand. This is on top of the 40 to 50 percent annual increase in its capital spending budget to more than the US$1.7 billion to announced in February. About half of the equipment capital expenditure would be spent on leading-edge and advanced packaging and testing technology, the company said. ASE is considered by analysts